Not provided
Not provided
Not provided
Not provided
Not provided
inadequate recruitment despite efforts
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Acute pancreatitis (AP) represents a critical health concern nationwide, with estimated 274,000 admissions annually and at a cost of 2.6 billion dollars. Current treatment strategies for AP are limited to supportive care with fluid resuscitation, analgesia, nutrition and prevention of end organ damage. Abdominal pain is often the predominant symptom in patients with AP and is treated with analgesics. As there is currently no disease-specific medical treatment to change the natural history of pancreatitis, pain control remains central to the treatment of AP. Among the analgesics, opioids have been shown to be provide safe and effective pain control in patients with AP. Current literature shows that there is no difference in the risk of pancreatitis complications or clinically serious adverse events between opioids and other analgesia options. Among hospitalized AP patients, adequate pain control often requires the use of intravenous (IV) opiates in the first 24-48 hours, which can later be transitioned to oral (PO) opioids. While there are various methods of delivering opioid medications such as IV, PO, and transdermal to name a few, IV opioids are commonly administered, either on a scheduled and/or on an as needed (PRN) basis as directed by the attending physician. In contrast to the conventional, method of physician directed IV opioid delivery, patient-controlled analgesia (PCA) is a form of IV opioid medication delivery in which the patient can rapidly titrate the opioid dose to manage variable levels of pain. This modality of opioid administration is often preferred by patients and has been widely used in postsurgical and obstetric patients to effectively treat their pain. PCA allows for faster intervention on pain limiting time to treatment and peak pain levels and has also been shown to decrease total opioid dose. However, there is limited evidence in published literature assessing the feasibility of using PCA to treat the pain of AP or comparing its efficacy and safety profile compared to the more traditional physician directed analgesia. One retrospective study has shown that use of PCA was surprisingly associated with longer hospital stays and higher rates of outpatient opioid use when compared to routine physician-directed analgesia (PDA), however there are no prospective trials to study this comparison. Hence, in this study, the investigators will compare the effects of using PCA among patients with AP to that of conventional PDA.
Investigators will identify patients with AP based on the 2012 revised Atlanta criteria for diagnosis, i.e., AP is diagnosed if 2 out of the following 3 criteria are met:
Acute onset of persistent, severe, epigastric pain often radiating to the back,
Elevation in serum lipase or amylase to three times or greater than the upper limit of normal,
Characteristic findings of acute pancreatitis on imaging (contrast-enhanced computed tomography [CT], magnetic resonance imaging [MRI], or transabdominal ultrasonography).
Patients will be recruited for participation in this study while they are hospitalized with AP at Beth Israel Deaconess Medical Center. Once the patient has been transferred from the emergency department to the hospital floor, we will identify and recruit them for participation in our study.
After obtaining informed consent from the patient, the patient will be enrolled by simple randomization to either the PCA or the PDA arm of the study. The research staff will assign patients to either the PCA arm or the PDA arm based on a standard randomization. Once, a patient has consented, the research staff will assign them to the next sequential study identidication number and corresponding study arm and let the attending hospitalist know of the result. The patient will then be enrolled in their assigned arm.
The initial protocol for analgesic administration in each arm is as follows:
Recommended algorithm for physician directed analgesia (PDA) arm:
Recommended algorithm for patient controlled analgesia (PCA) arm:
Recommended for all patients:
Recommended algorithm for transition to oral:
Dosing and frequencies of medications in the above algorithms are recommendations. The recommended doses are not required for maintenance in the study and we anticipate that they may change given patient characteristics and variable response to medication, the rapidly evolving nature of acute pancreatitis, and hospitalist preferences. However, the mode of IV opioid administration (PDA vs PCA) should remain as assigned until transition to PO opioid.
Each patient will be closely monitored for adverse events related to opioid administration to include cardiorespiratory decompensation, hemodynamic instability, nausea, vomiting, confusion, altered mental status, headache, drowsiness, etc. This monitoring will include continuous pulse oximetry in addition to vital sign measurement every 4 hours.
The efficacy of each treatment arm to adequately control the patient's pain will be assessed with scheduled use of the Numeric Rating Scale (NRS) every 4 hours by the nursing staff. Pain rating on the NRS will be documented by the nursing staff after each assessment. In an NRS, patients are asked to circle the number between 0 and 10 that fits best to their pain intensity. Zero usually represents 'no pain at all' whereas 10 represents 'the worst pain ever possible'.
Likert scale of 1 to 10 (1 = Very poor, 10= excellent) will be used to grade overall patient satisfaction with pain control.
Once each patient's pain is well controlled on IV opioid administration (as determined by the attending physician) and they can tolerate intake by mouth, transition from IV to PO opioid medication can be made in each arm by the attending physician. If the patient is unable to tolerate either the PDA or the PCA arm for any reason and requires switching over to the other arm as part of his/her clinical care, they will be withdrawn from the study and their data will be excluded while analyzing the results. AP has a variable course and may require IV opioids after transition to PO opioids. The modality of IV opioid administration will revert to the assigned treatment arm.
Other aspects of each patient's routine clinical care will continue as per the attending physician under whom the patient is admitted regardless of treatment arm status (PDA vs PCA).
At the end of their hospital stay, investigators will document study outcomes.
Investigators expect to enroll patients over a 36-month period from the start date of the study. Based on this, investigators expect patient enrollment to end by 4/30/2024. Investigators will plan to perform data analysis at two points: 1. Interim data analysis at a predetermined point in the study (mid-point of study), and 2. At the end of the study once patient enrollment has been completed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient controlled analgesia (PCA) group | Patients in this group will be allocated to the PCA arm, i.e., they will be receiving a PCA pump for administration of opioids. |
| |
| Physician directed analgesia (PDA) group | Patients in this group will be allocated to the PDA arm, i.e., they will be receiving opioids administered by the nurse, as and when directed by the physician. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Opioid | Drug | Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse. |
| Measure | Description | Time Frame |
|---|---|---|
| Length of Stay (Days) | amount of time enrolled participants are admitted to the hospital. | 4-21 days |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Days the Patient Gets Nothing by Mouth (NPO) Before Diet is Initiated | The duration of time between patient presentation and dietary advancement was noted. | From date of hospital admission to discharge, assessed up to 12 days |
| Mean Pain Scores on a Numeric Rating Scale (NRS) Over the First 24 Hours and Over Entire Course of Their Hospital Stay |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients diagnosed with acute pancreatitis who are admitted to our hospital (BIDMC) and meet above mentioned inclusion criteria will be enrolled in the study.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
All the 7 patients underwent assignment to both the treatment groups
The participants were recruited from a single tertiary care center. The first patient was recruited on 2/22/2022 and the last patient on 10/17/2023.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Patient Controlled Analgesia (PCA) Group | Patients in this group will be allocated to the PCA arm, i.e., they will be receiving a PCA pump for administration of opioids. Opioid: Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse. |
| FG001 | Physician Directed Analgesia (PDA) Group | Patients in this group will be allocated to the PDA arm, i.e., they will be receiving opioids administered by the nurse, as and when directed by the physician. Opioid: Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
We anticipated a non-parametric distribution of age which warranted description as median (IQR). Sex and ethnoracial distribution were described as frequency (percentage).
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Physician Directed Analgesia (PDA) Group | Patients in this group will be allocated to the PDA arm, i.e., they will be receiving opioids administered by the nurse, as and when directed by the physician. Opioid: Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Length of Stay (Days) | amount of time enrolled participants are admitted to the hospital. | Posted | Mean | Standard Deviation | days | 4-21 days |
|
1 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Patient Controlled Analgesia (PCA) Group | Patients in this group will be allocated to the PCA arm, i.e., they will be receiving a PCA pump for administration of opioids. Opioid: Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse. |
Not provided
Not provided
Early termination leading to small numbers of subjects analyzed
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Sunil Sheth | Beth Israel Deaconess Medical Center | 6176675576 | ssheth@bidmc.harvard.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 2, 2021 | Dec 19, 2023 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D010195 | Pancreatitis |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000701 | Analgesics, Opioid |
| ID | Term |
|---|---|
| D009294 | Narcotics |
| D002492 | Central Nervous System Depressants |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
Not provided
Not provided
Not provided
Not provided
Not provided
|
Mean pain scores over the first 24 hours, second 24 hours, and course of their hospital stay were recorded using a numeric rating scale which ranged from 0 to 10 where 0 is no pain and 10 is the worst pain imaginable. |
| Day 1 of hospitalization and Average Pain Score throughout entire hospital stay, assessed up to 12 days |
| Total Morphine Milligram Equivalent | The total opioid dose for pain control was quantified through Total morphine milligram equivalent which was calculated based on the standardized conversion of opioids. | Through hospital stay, an average of 5-7 days |
| Time to Transition to PO Opioids | The time from the transition of IV opioids to PO opioids was recorded. | Through hospital stay, an average of 5-7 days |
| Number of Participants With Opioid-related Adverse Events | Opioid-related adverse events were prospectively collected. | Through hospital stay, an average of 5-7 days |
| Number of Participants With Use of Naloxone and Antiemetics | Use of naloxone and antiemetics was noted for each recruited subject. | Through hospital stay, an average of 5-7 days |
| Number of Participants With ICU Transfer | Transfer of patients to the intensive care unit was prospectively noted. | Through hospital stay, an average of 5-7 days |
| Number of Participants With 30-day Readmission | The 30-day readmission rates were prospectively noted. | 30 days |
| All-cause Inpatient Mortality and Opioid-related Inpatient Mortality | All-cause inpatient mortality and opioid-related inpatient mortality were recorded. | Through hospital stay, an average of 5-7 days |
| 30-day Mortality | 30-day mortality was prospectively noted. | 30 days |
| Daily Morphine Milliequivalents on Discharge | Daily morphine milliequivalents on discharge were recorded prospectively | Through hospital stay, an average of 5-7 days |
| BG001 | Patient Controlled Analgesia (PCA) Group | Patients in this group will be allocated to the PCA arm, i.e., they will be receiving a PCA pump for administration of opioids. Opioid: Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG001 | Physician Directed Analgesia (PDA) Group | Patients in this group will be allocated to the PDA arm, i.e., they will be receiving opioids administered by the nurse, as and when directed by the physician. Opioid: Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse. |
|
|
| Secondary | Number of Days the Patient Gets Nothing by Mouth (NPO) Before Diet is Initiated | The duration of time between patient presentation and dietary advancement was noted. | Posted | Mean | Standard Deviation | days | From date of hospital admission to discharge, assessed up to 12 days |
|
|
|
| Secondary | Mean Pain Scores on a Numeric Rating Scale (NRS) Over the First 24 Hours and Over Entire Course of Their Hospital Stay | Mean pain scores over the first 24 hours, second 24 hours, and course of their hospital stay were recorded using a numeric rating scale which ranged from 0 to 10 where 0 is no pain and 10 is the worst pain imaginable. | Posted | Mean | Standard Deviation | units on a scale | Day 1 of hospitalization and Average Pain Score throughout entire hospital stay, assessed up to 12 days |
|
|
|
| Secondary | Total Morphine Milligram Equivalent | The total opioid dose for pain control was quantified through Total morphine milligram equivalent which was calculated based on the standardized conversion of opioids. | Posted | Mean | Standard Deviation | morphine milligram equivalents | Through hospital stay, an average of 5-7 days |
|
|
|
| Secondary | Time to Transition to PO Opioids | The time from the transition of IV opioids to PO opioids was recorded. | Posted | Mean | Standard Deviation | days | Through hospital stay, an average of 5-7 days |
|
|
|
| Secondary | Number of Participants With Opioid-related Adverse Events | Opioid-related adverse events were prospectively collected. | Posted | Count of Participants | Participants | Through hospital stay, an average of 5-7 days |
|
|
|
| Secondary | Number of Participants With Use of Naloxone and Antiemetics | Use of naloxone and antiemetics was noted for each recruited subject. | Posted | Count of Participants | Participants | Through hospital stay, an average of 5-7 days |
|
|
|
| Secondary | Number of Participants With ICU Transfer | Transfer of patients to the intensive care unit was prospectively noted. | Posted | Count of Participants | Participants | Through hospital stay, an average of 5-7 days |
|
|
|
| Secondary | Number of Participants With 30-day Readmission | The 30-day readmission rates were prospectively noted. | Posted | Count of Participants | Participants | 30 days |
|
|
|
| Secondary | All-cause Inpatient Mortality and Opioid-related Inpatient Mortality | All-cause inpatient mortality and opioid-related inpatient mortality were recorded. | Posted | Count of Participants | Participants | Through hospital stay, an average of 5-7 days |
|
|
|
| Secondary | 30-day Mortality | 30-day mortality was prospectively noted. | Posted | Count of Participants | Participants | 30 days |
|
|
|
| Secondary | Daily Morphine Milliequivalents on Discharge | Daily morphine milliequivalents on discharge were recorded prospectively | Posted | Mean | Standard Deviation | morphine milligram equivalents | Through hospital stay, an average of 5-7 days |
|
|
|
| 0 |
| 3 |
| 0 |
| 3 |
| 0 |
| 3 |
| EG001 | Physician Directed Analgesia (PDA) Group | Patients in this group will be allocated to the PDA arm, i.e., they will be receiving opioids administered by the nurse, as and when directed by the physician. Opioid: Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse. | 0 | 4 | 0 | 4 | 0 | 4 |
Not provided
Not provided
| D020164 | Chemical Actions and Uses |
| D000700 | Analgesics |
| D018689 | Sensory System Agents |
| D018373 | Peripheral Nervous System Agents |
| D002491 | Central Nervous System Agents |
| D045506 | Therapeutic Uses |